🟢 AstraZeneca is trading 3.38% up in pre-market after Q3 revenue and core EPS beat estimates

AstraZeneca is trading at $180.30 (+3.38%) after Q3 revenue and core EPS beat analyst expectations.

• Q3 revenue was $16.21 billion versus $15.99 billion expected; core EPS was $2.79 versus $2.59 expected.
• Growth in oncology, respiratory and immunology, and rare diseases helped offset generic competition for older medicines.
• The company reiterated its 2026 guidance.